选择性环氧化酶-2 抑制剂相关的不良心血管事件研究进展

www.yongyao.net　　2009-11-20 15:59:04　　来源：　　责任编辑：

分享到：

【参考文献】
[1 ] Bombardier C , Laine L , Reicin A , et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group [J ] . N Engl J Med. 2000 , 343(21) :1520 - 1528.
[2 ] Tanaka Y, Ward SL , Smith WL. Immunochemical and kinetic evidence for two different prostaglandin H2prostaglandin E isomerases in sheep vesicular gland microsomes [J ] . J Biol Chem, 1987 , 262 (3) :1374 - 1381.
[3 ] Baker CS , Hall RJ , Evans TJ , et al . Cyclooxygenase22 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and co2localizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages [J ] . Arterioscler Thromb VascBiol , 1999 , 19(3) : 646 - 655.
[4 ] Schonbeck U , Sukhova GK, Graber P , et al . Augmented expression of cyclooxygenase22 in human atherosclerotic lesions [J ] . AmJ Pathol ,1999 , 155 (4) : 1281 - 1291.
[5 ] Chenevard R , Hurlimann D , Bechir M, et al . Selective COX22 inhibition improves endothelial function in coronary artery disease [J ] . Circulation , 2003 , 107(3) : 405 - 409.
[ 6 ] WidlanskyME , Price DT , Gokce N , et al . Short2 and long2term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension[J ] . Hypertension , 2003 , 42(3) : 310 - 315.
[7 ] Cullen L , Kelly L , Connor SO , et al . Selective cyclooxygenase22 inhibition by nimesulide in man [J ] . J Pharmacol Exp Ther , 1998 , 287(2) : 578 - 582.
[8 ] McAdam BF , Catella2Lawson F , Mardini IA , et al . Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)22 : the human pharmacology of a selective inhibitor of COX22 [J ] . Proc Natl Acad Sci U S A ,1999 , 96 (1) : 272 - 277.
[9 ] Caughey GE , Cleland LG, Penglis PS , et al . Roles of cyclooxygenase(COX)-1 and COX22 in prostanoid production by human endothelialcells : selective up2regulation of prostacyclin synthesis by COX22 [J ] . JImmunol , 2001 , 167 (5) : 2831 - 2838.
[10 ] Egan KM, Wang M, Fries S , et al . Cyclooxygenases , thromboxane ,and atherosclerosis : plaque destabilization by cyclooxygenase22 inhibition combined with thromboxane receptor antagonism [J ] . Circulation ,2005 , 111 (3) : 334 - 342.
[11 ] Shinmura K, Tang XL , Wang Y, et al . Cyclooxygenase22 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits [J ] . Proc Natl Acad Sci U S A , 2000 , 97(18) :10197 - 10202.
[12 ] Birnbaum Y, Ye Y, Rosanio S , et al . Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia2reperfusion injury[J ] . Cardiovasc Res , 2005 , 65(2) : 345 - 355.
[13 ] Silverstein FE , Faich G, Goldstein JL , et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti2inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : A randomized controlledtrial . Celecoxib Long2term Arthritis Safety Study [J ] . JAMA , 2000 ,284(10) : 1247 - 1255.
[ 14 ] Bresalier RS , Sandler RS , Quan H , et al . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J ] .N Engl J Med , 2005 , 352(11) : 1092 - 1102.
[15 ] Solomon SD , McMurray JJ , Pfeffer MA , et al . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention [J ] . N Engl J Med , 2005 , 352 (11) : 1071 - 1080.
[16 ] Spektor G, Fuster V. Drug insight : cyclo2oxygenase 2 inhibitors and cardiovascular risk —where are we now ? [J ] . Nat Clin Pract CardiovascMed , 2005 , 2(6) : 290 - 300.
[17 ] Cardiovascular and Cerebrovascular Events in the Randomized , Controlled Alzheimer′s Disease Anti2Inflammatory Prevention Trial(ADAPT) [J ] . PLoS Clin Trials , 2006 , 1 (7) : e33.
[ 18 ] Singh G, Fort JG, Goldstein JL , et al . Celecoxib versus naproxen and diclofenac in osteoarthritis patients : SUCCESS2I Study [ J ] . Am JMed , 2006 , 119(3) : 255 - 266.
[ 19 ] On2going Trial , See : http : / / clinicaltrials. gov/ ct/ show/NCT00346216.
[20 ] Nussmeier NA , Whelton AA , Brown MT , et al . Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery [J ] . NEngl J Med , 2005 , 352 (11) : 1081 - 1091.
[21 ] Ott E , Nussmeier NA , Duke PC , et al . Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery [ J ] . J Thorac Cardiovasc Surg ,2003 , 125 (6) : 1481 - 1492.
[22 ] Farkouh ME , Kirshner H , Harrington RA , et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) , cardiovascular outcomes : randomised controlled trial [J ] . Lancet , 2004 , 364 (9435) :
675 - 684.
[23 ] Topol EJ , Falk GW. A coxib a day won’t keep the doctor away [J ] .Lancet . 2004. 364 (9435) : 639 - 640.
[24 ] Cannon CP , Curtis SP , FitzGerald GA , et al . Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long2term (MEDAL) programme : a randomised comparison
[J ] . Lancet , 2006 , 368 (9549) : 1771 - 1781.
[25 ] Johnson AG, Nguyen TV , Day RO. Do nonsteroidal anti2inflammatory drugs affect blood pressure A meta2analysis [ J ] . Ann Intern Med ,1994 , 121 (4) : 289 - 300.
[26 ] Aw TJ , Haas SJ , Liew D , et al . Meta2analysis of cyclooxygenase2 inhibitors and their effects on blood pressure [J ] . Arch Intern Med ,2005 , 165 (5) : 490 - 496.
[ 27 ] Page J , Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients : an underrecognized public health problem [J ] . Arch Intern Med , 2000 , 160(6) : 777 - 784.
[28 ] Feenstra J , Heerdink ER , Grobbee DE , et al . Association of nonsteroidal anti2inflammatory drugs with first occurrence of heart failure and with relapsing heart failure : the Rotterdam Study [ J ] . Arch Intern Med , 2002 , 162(3) : 265 - 270.
[29 ] Mamdani M, Juurlink DN , Lee DS , et al . Cyclo2oxygenase22 inhibitors versus non2selective non2steroidal anti2inflammatory drugs and congestive heart failure outcomes in elderly patients : a population2based cohort study [J ] . Lancet , 2004 , 363(9423) : 1751 - 1756.
[30 ] Hudson M, Richard H , Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib , rofecoxib , or nonsteroidal anti2inflammatory drugs : population based study [J ] . BMJ ,2005 , 330 (7504) : 1370.
[31 ] Zhang J , Ding EL , Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events : meta2analysis of randomized trials [J ] . JAMA , 2006 , 296 (13) : 1619 - 1632.